Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.48 |
| ▸ | ITGAV | P06756 | 8/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157097 | 1.00 | TBXAS1 (0.50) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| SCHEMBL157096 | 1.00 | TBXAS1 (0.50) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| SCHEMBL30829068 | 1.00 | TBXAS1 (0.50) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL7145554 | 0.98 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL7145559 | 0.98 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL6777920 | 0.98 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL6786456 | 0.98 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Cadaverine Tartrate SCHEMBL6954532 | 0.92 | KDM4E (0.54) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Cadaverine Tartrate SCHEMBL6954517 | 0.92 | KDM4E (0.54) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B | |
| Trifluoroacetic Acid SCHEMBL9264022 | 0.91 | TBXAS1 (0.44) | TBXAS1SMN1; SMN2ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-20200216836-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20190330618-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2019-10-31 | — | — | US | disclosed |
| US-10287576-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2019-05-14 | — | — | US | disclosed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| EP-2341140-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | disclosed |
| EP-1957644-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2009-10-22 | — | — | US | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6849639-B2 | Anticancer agents, antiinflamatory agents, osteoporosis, atherosclerosis | AMGEN INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1240158-A1 | 1-(AMINOPHENYL)-2-PYRROLIDONES AS INTEGRIN INHIBITORS | Amgen Inc., (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020019402-A1 | Integrin inhibitors and their methods of use | AMGEN INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001044230-A1 | 1-(AMINOPHENYL)-2-PYRROLIDONES AS INTEGRIN INHIBITORS | AMGEN INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019402-A1 | Integrin inhibitors and their methods of use | ITGB3, ITGA5, ITGB5 | TBXAS1 474/4885SMN1; SMN2 1945/4885ITGB3 1/4885 |
| US-20090264300-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | RNGTT, DUT, EMG1 | TBXAS1 1100/4885SMN1; SMN2 3626/4885ITGB3 3814/4885 |
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | TBXAS1 396/4885SMN1; SMN2 3856/4885ITGB3 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.